



CIN-L24230GJ1995PLC025878

Cadila
Healthcare Limited**Regd. Office :**

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

August 29, 2014

Bombay Stock Exchange Limited

1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Sanjay Golecha
Mr. Gopalkrishnan

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited

Kamdheni Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Re.: Press Release.

Dear Sir / Madam

We enclose herewith a copy of press release dated August 29, 2014 under the title "**Zydus receives final approval for Telmisartan Tablets**" to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED

UPEN H. SHAH

COMPANY SECRETARY

Encl.: As above.



Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Zydus receives final approval for Telmisartan Tablets

Ahmedabad, 29 August 2014

Zydus Cadila has received the final approval from the USFDA to market Telmisartan Tablets, 20mg, 40mg and 80mg.

The estimated sales in 2014 for Telmisartan Tablets which fall in the anti-hypertensive segment is USD 233.3 million, as per IMS.

The group now has 96 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.
